February 2008, Volume 38 Number 2 , p 30 - 30 [FREE]



function openWeblink(url,target,width) { if (!width) width = '100%'; var newWindow; newWindow =,target,'width='+width+',height=480,status,resizable,titlebar,toolbar,scrollbars'); newWindow.focus(); } function set_JnlFullText_Print() { metaTag = document.createElement('meta'); metaTag.setAttribute('name','OvidPageId'); metaTag.setAttribute('content','JnlFullText_Print'); head = document.getElementsByTagName('head')[0]; head.appendChild(metaTag); return; } if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+) window.addEventListener('onload',set_JnlFullText_Print(),false); } else if (window.attachEvent) { // IE 5+ Event Model window.attachEvent('onload',set_JnlFullText_Print); } // For anything else, just don't add the event Full Text   #header-block { display: none; } © 2008 Lippincott Williams & Wilkins, Inc. Volume 38(2), February 2008, p 30 Avandia gets black-box label change [Department: upFront: DRUG NEWS: DIABETES]

Avandia, ...


Avandia, the popular type 2 diabetes drug, will have a revised black-box label warning of its associated heart attack risks, announced GlaxoSmithKline, the drug's maker. Despite mandating this labeling change, FDA officials aren't seeking to have rosiglitazone (Avandia) pulled from the market because evidence of the drug's heart attack risk is inconclusive. According to an FDA official, there simply isn't enough evidence to indicate that heart attack risks are any higher with Avandia than other type 2 diabetes drugs.


The FDA advises health care providers to monitor patients with type 2 diabetes who are at cardiac risk and are taking Avandia. For more information about the labeling changes, visit